NantKwest Doses First Patient in Phase 2 Single-Arm Trial of Metastatic Merkel Cell Carcinoma Therapy With Off-the-Shelf CD16 Natural Killer Cells

Stock Information for NantKwest Inc.

Loading

Please wait while we load your information from QuoteMedia.